The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer

Runzhi Huang; Jiaqi Zhang; Mingxiao Li; Penghui Yan; Huabin Yin; Suna Zhai; Xiaolong Zhu; Peng Hu; Jiaxin Zhang; Ling Huang; Man Li; Zehui Sun; Tong Meng; Daoke Yang; Zongqiang Huang

doi:10.1155/2020/6527564

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer

PPAR Res. 2020 Sep 22:2020:6527564. doi: 10.1155/2020/6527564. eCollection 2020.

Authors

Runzhi Huang^{1

2

3}, Jiaqi Zhang¹, Mingxiao Li¹, Penghui Yan¹, Huabin Yin⁴, Suna Zhai⁵, Xiaolong Zhu¹, Peng Hu¹, Jiaxin Zhang¹, Ling Huang¹, Man Li¹, Zehui Sun¹, Tong Meng^{4

6}, Daoke Yang⁵, Zongqiang Huang¹

Affiliations

¹ Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, 1 East Jianshe Road, Zhengzhou, China.
² Division of Spine, Department of Orthopedics, Tongji Hospital Affiliated to Tongji University School of Medicine, 389 Xincun Road, Shanghai, China.
³ Tongji University School of Medicine, 1239 Siping Road, Shanghai 200092, China.
⁴ Department of Orthopedics, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, 100 Haining Road, Shanghai, China.
⁵ Department of Radiotherpy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
⁶ Tongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Tongji University, Shanghai, China.

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of nuclear transcription factors. The functions of the PPAR family (PPARA, PPARD, and PPARG) and their coactivators (PPARGC1A and PPARGC1B) in maintenance of lipid and glucose homeostasis have been unveiled. However, the roles of PPARs in cancer development remain elusive. In this work, we made use of 11,057 samples across 33 TCGA tumor types to analyze the relationship between PPAR transcriptional expression and tumorigenesis as well as drug sensitivity. We performed multidimensional analyses on PPARA, PPARG, PPARD, PPARGC1A, and PPARGC1B, including differential expression analysis in pan-cancer, immune subtype analysis, clinical analysis, tumor purity analysis, stemness correlation analysis, and drug responses. PPARs and their coactivators expressed differently in different types of cancers, in different immune subtypes. This analysis reveals various expression patterns of the PPAR family at a level of pan-cancer and provides new clues for the therapeutic strategies of cancer.